Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sen. Murray Prods FDA To Clarify 510(k) Modification Policies In Superbug Bill

This article was originally published in The Gray Sheet

Executive Summary

Following up on recommendations made in her January report on duodenoscope contamination, Senate HELP Ranking Member Patty Murray, D-Wash., introduced a bill pressing FDA to accelerate its work to clarify when 510(k)s are needed for device modifications and to solidify the agency's authority to deny submissions if the sponsor fails to provide validated reprocessing data.

You may also be interested in...



510(k) Modifications Guidance Docs Finalized At Long Last

After years of controversy, US FDA finally succeeded in updating its 20-year-old guideline on when a new 510(k) is needed for device modifications. Split out as its own document is a guideline targeting the issue specifically for software modifications.

FDA Calls For Full Risk Reviews For Device Changes In 510(k) Modifications Draft

US FDA wants sponsors to complete risk-based assessments and thoroughly consider unintended outcomes of changes they make to already-cleared devices, says a new, highly anticipated draft guidance on 510(k) modifications. This is true whether alterations are made by manufacturers to improve safety or effectiveness, enhance labels, change technology or engineering, or to upgrade materials in a device.

CEOs Want Anti-Kickback, Self-Referral Law Waivers For ACO Interactions

The Healthcare Leadership Council – a coalition of health care CEOs – wants Congress to allow more waivers for accountable care organizations from the anti-kickback statute and the Stark law, which protects against physician self-referrals, and are also pushing the same slate of device regulatory reforms as in the House-approved 21st Century Cures bill.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

MT034936

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel